Biomea Fusion, Inc. Profile Avatar - Palmy Investing

Biomea Fusion, Inc.

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioava…

Biotechnology
US, Redwood City [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Biomea Fusion, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of BMEA's Analysis
CIK: 1840439 CUSIP: 09077A106 ISIN: US09077A1060 LEI: - UEI: -
Secondary Listings
BMEA has no secondary listings inside our databases.